Med BioGene Posts Slightly Higher Q2 Loss as Lung Cancer Test Nears Commercialization | GenomeWeb

NEW YORK (GenomeWeb News) – Med BioGene today reported a second quarter net loss of C$139,171 (US$132,159), up slightly from a net loss of C$102,121 for the second quarter of 2012.

The Vancouver, British Columbia-based molecular diagnostics developer didn't report any revenues for the quarter. It noted that its commercialization partner, Precision Therapeutics, recently completed the final clinical studies on the firm's GeneFx Lung test and expects to launch the assay in the US as a CLIA waived test this fall.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.